Key result
Bevacizumab treatment in metastatic breast cancer can induce acute congestive heart failure, which showed favorable evolution after drug discontinuation and adequate therapy.
Bevacizumab can cause acute congestive heart failure, which may resolve favorably upon discontinuation and appropriate heart failure treatment.
May warrant cardiac monitoring with bevacizumab; leaves open incidence, mechanisms, and management in larger cohorts.
treatment. The evolution of CHF was favorable after adequate treatment and discontinuation of Bevacizumab as in most cases reported in the literature.
No takes yet. Share an insight, caveat, or question.
Akimana et al. (2022) studied this question. Bevacizumab treatment in metastatic breast cancer can induce acute congestive heart failure, which showed favorable evolution after drug discontinuation and adequate therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: